[The use of diammonium glycyrrhizinate in the treatment of hepatic dysfunction in burn patients].
OBJECTIVE
To observe the protective effect of diammonium glycyrrhizinate on hepatic function in burn patients.


METHODS
Twenty burn patients with hepatic dysfunction were enrolled in the study and were randomly divided into 2 groups, i. e. treatment (T, n = 10, with conventional treatment and intravenous infusion of 150 mg diammonium glycyrrhizinate per day for 14 days), and control (C, n = 10, with conventional treatment) groups. The blood samples in both groups were collected before and 7 and 15 days after the treatment. The serum contents of ALT, AST, GGT, ALP and PA in the blood samples were determined and analyzed comparatively.


RESULTS
There was obvious difference in the serum contents of ALT, AST, GGT, ALP and PA in the T group before treatment (168 +/- 46 U/L, 104 +/- 29 U/L, 162 +/- 37 U/L, 149 +/- 17 U/L, 310 +/- 35 mg/L, respectively) and 15 days after treatment (51 +/- 9 U/L, 31 +/- 3 U/L, 56 +/- 10 U/L, 103 +/- 9 U/L, 372 +/- 44 mg/L, respectively, P < 0.05). There was no difference in these indices in the C group before and after treatment (P > 0.05).


CONCLUSIONS
Diammonium glycyrrhizinate seemed to be beneficial to the management of postburn hepatic dysfunction with obvious rapid depression of hepatic enzymes.
Jin
Han-hong
HH
Department of Burns , Special Hospital of Burns , Hangzhou 310021, P. R. China.
Zheng
Guo-ping
GP
Chen
Wu-rong
WR
Liu
Dan
D
Cheng
Xiang
X
Ren
Jia-biao
JB
D000328:Adult; D000410:Alanine Transaminase / Q000097:blood; D001219:Aspartate Aminotransferases / Q000097:blood; D002056:Burns / Q000097:blood / Q000188:drug therapy* / Q000503:physiopathology*; D005260:Female; D019695:Glycyrrhizic Acid / Q000627:therapeutic use*; D006801:Humans; D008099:Liver / Q000503:physiopathology; D008107:Liver Diseases / Q000188:drug therapy*; D008111:Liver Function Tests; D008297:Male; D008875:Middle Aged
D019695:Glycyrrhizic Acid; D001219:Aspartate Aminotransferases; D000410:Alanine Transaminase